Foresite Capital is a private equity firm that is dedicated to healthcare; it was founded in 2011 by Jim Tananbaum, whom is the current CEO of the company. Before Foresite Capital, Mr. Tananbaum founded GelTex Pharmaceuticals. GelTex was acquired in 1998 for $1.6 billion,At that time Renagel (Renzela)was making a little more than $200 million a year; now, estimated to make $1 billion, 22 years later. Also CEO and co-founder of Theravance, Inc., the CEO of two companies worth about $3.2 billion.
Foresite’s biggest investment is a new drug called “Intarcia”, it is implanted twice a year into type I diabetes patients, aiding them to lose weight and control their blood sugar levels. This new drug has the potential to help 350 million people all over the globe, who are suffering from diabetes due to being over-weight, when it launches at the end of 2017. Visit Medium for more info.
Aeri Pharmaceuticals, yet another investment of Jim Tananbaum’s Foresite, has come up with a once a day treatment for glaucoma. Glaucoma being the number one cause of over 40 million people in the world to go blind.
Jim Tananbaum has an extensive educational background. Majoring at Yale in mathematics, computer science, and electrical engineering. Then on to earning his M.D. and M.B.A at Harvard, and finally an M.S. at the Massachusetts Institute of Technology.
Foresite was the brain child of over 25 years as an entrepreneur in the healthcare industry. To Jim, Foresite is understanding the future of health care. He has invested in 77 healthcare companies. Including bio-pharmaceuticals, medical services, diagnostics and genomic sequencing.
Jim Tananbaum is not only the CEO of two healthcare companies he founded and co-founded; he is also a philanthropist, with the many investments his companies continue to making towards new healthcare technologies which are helping people worldwide to live longer, healthier lives.
See more: https://ideamensch.com/jim-tananbaum/